Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy: results of the large, single‐arm, open‐label phase IIIb CONSIGN study
This article reports the results of the CONSIGN study, which was designed to characterize the safety of regorafenib in a large patient population, estimate progression‐free survival, and provide patients with treatment‐refractory metastatic colorectal cancer access to regorafenib before market autho...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2019
|
| In: |
The oncologist
Year: 2018, Jahrgang: 24, Heft: 2, Pages: 185-192 |
| ISSN: | 1549-490X |
| DOI: | 10.1634/theoncologist.2018-0072 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1634/theoncologist.2018-0072 Verlag, lizenzpflichtig, Volltext: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369948/ 
|
| Verfasserangaben: | Eric Van Cutsem, Erika Martinelli, Stefano Cascinu, Alberto Sobrero, Maria Banzi, Jean‐François Seitz, Carlo Barone, Marc Ychou, Marc Peeters, Baruch Brenner, Ralf Dieter Hofheinz, Evaristo Maiello, Thierry André, Andrea Spallanzani, Rocio Garcia‐Carbonero, Yull E. Arriaga, Udit Verma, Axel Grothey, Christian Kappeler, Ashok Miriyala, Joachim Kalmus, Alfredo Falcone, Alberto Zaniboni |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1691851124 | ||
| 003 | DE-627 | ||
| 005 | 20220818010431.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200306r20192018xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1634/theoncologist.2018-0072 |2 doi | |
| 035 | |a (DE-627)1691851124 | ||
| 035 | |a (DE-599)KXP1691851124 | ||
| 035 | |a (OCoLC)1341309705 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Van Cutsem, Eric |e VerfasserIn |0 (DE-588)142064475 |0 (DE-627)704133164 |0 (DE-576)327693886 |4 aut | |
| 245 | 1 | 0 | |a Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy |b results of the large, single‐arm, open‐label phase IIIb CONSIGN study |c Eric Van Cutsem, Erika Martinelli, Stefano Cascinu, Alberto Sobrero, Maria Banzi, Jean‐François Seitz, Carlo Barone, Marc Ychou, Marc Peeters, Baruch Brenner, Ralf Dieter Hofheinz, Evaristo Maiello, Thierry André, Andrea Spallanzani, Rocio Garcia‐Carbonero, Yull E. Arriaga, Udit Verma, Axel Grothey, Christian Kappeler, Ashok Miriyala, Joachim Kalmus, Alfredo Falcone, Alberto Zaniboni |
| 264 | 1 | |c 2019 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 06.03.2020 | ||
| 500 | |a Published online: September 6, 2018 | ||
| 520 | |a This article reports the results of the CONSIGN study, which was designed to characterize the safety of regorafenib in a large patient population, estimate progression‐free survival, and provide patients with treatment‐refractory metastatic colorectal cancer access to regorafenib before market authorization. | ||
| 534 | |c 2018 | ||
| 700 | 1 | |a Martinelli, Erika |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cascinu, Stefano |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sobrero, Alberto |e VerfasserIn |4 aut | |
| 700 | 1 | |a Banzi, Maria |e VerfasserIn |4 aut | |
| 700 | 1 | |a Seitz, Jean‐François |e VerfasserIn |4 aut | |
| 700 | 1 | |a Barone, Carlo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ychou, Marc |e VerfasserIn |4 aut | |
| 700 | 1 | |a Peeters, Marc |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brenner, Baruch |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hofheinz, Ralf-Dieter |d 1969- |e VerfasserIn |0 (DE-588)121917517 |0 (DE-627)08161876X |0 (DE-576)292991568 |4 aut | |
| 700 | 1 | |a Maiello, Evaristo |e VerfasserIn |4 aut | |
| 700 | 1 | |a André, Thierry |e VerfasserIn |4 aut | |
| 700 | 1 | |a Spallanzani, Andrea |e VerfasserIn |4 aut | |
| 700 | 1 | |a Garcia‐Carbonero, Rocio |e VerfasserIn |4 aut | |
| 700 | 1 | |a Arriaga, Yull E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Verma, Udit |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grothey, Axel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kappeler, Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Miriyala, Ashok |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kalmus, Joachim |e VerfasserIn |4 aut | |
| 700 | 1 | |a Falcone, Alfredo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zaniboni, Alberto |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The oncologist |d Oxford : Oxford University Press, 1996 |g 24(2019), 2, Seite 185-192 |h Online-Ressource |w (DE-627)32063020X |w (DE-600)2023829-0 |w (DE-576)281196338 |x 1549-490X |7 nnas |a Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy results of the large, single‐arm, open‐label phase IIIb CONSIGN study |
| 773 | 1 | 8 | |g volume:24 |g year:2019 |g number:2 |g pages:185-192 |g extent:8 |a Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy results of the large, single‐arm, open‐label phase IIIb CONSIGN study |
| 856 | 4 | 0 | |u https://doi.org/10.1634/theoncologist.2018-0072 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369948/ |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200306 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 121917517 |a Hofheinz, Ralf-Dieter |m 121917517:Hofheinz, Ralf-Dieter |d 60000 |d 61200 |e 60000PH121917517 |e 61200PH121917517 |k 0/60000/ |k 1/60000/61200/ |p 11 | ||
| 999 | |a KXP-PPN1691851124 |e 3604869579 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"doi":["10.1634/theoncologist.2018-0072"],"eki":["1691851124"]},"origin":[{"dateIssuedDisp":"2019","dateIssuedKey":"2019"}],"title":[{"title_sort":"Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy","title":"Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy","subtitle":"results of the large, single‐arm, open‐label phase IIIb CONSIGN study"}],"person":[{"display":"Van Cutsem, Eric","given":"Eric","role":"aut","family":"Van Cutsem"},{"display":"Martinelli, Erika","family":"Martinelli","role":"aut","given":"Erika"},{"display":"Cascinu, Stefano","family":"Cascinu","given":"Stefano","role":"aut"},{"display":"Sobrero, Alberto","family":"Sobrero","given":"Alberto","role":"aut"},{"given":"Maria","role":"aut","family":"Banzi","display":"Banzi, Maria"},{"role":"aut","given":"Jean‐François","family":"Seitz","display":"Seitz, Jean‐François"},{"role":"aut","given":"Carlo","family":"Barone","display":"Barone, Carlo"},{"family":"Ychou","role":"aut","given":"Marc","display":"Ychou, Marc"},{"family":"Peeters","role":"aut","given":"Marc","display":"Peeters, Marc"},{"display":"Brenner, Baruch","family":"Brenner","role":"aut","given":"Baruch"},{"display":"Hofheinz, Ralf-Dieter","role":"aut","given":"Ralf-Dieter","family":"Hofheinz"},{"role":"aut","given":"Evaristo","family":"Maiello","display":"Maiello, Evaristo"},{"display":"André, Thierry","family":"André","role":"aut","given":"Thierry"},{"family":"Spallanzani","given":"Andrea","role":"aut","display":"Spallanzani, Andrea"},{"display":"Garcia‐Carbonero, Rocio","family":"Garcia‐Carbonero","role":"aut","given":"Rocio"},{"display":"Arriaga, Yull E.","given":"Yull E.","role":"aut","family":"Arriaga"},{"family":"Verma","given":"Udit","role":"aut","display":"Verma, Udit"},{"display":"Grothey, Axel","family":"Grothey","role":"aut","given":"Axel"},{"family":"Kappeler","role":"aut","given":"Christian","display":"Kappeler, Christian"},{"given":"Ashok","role":"aut","family":"Miriyala","display":"Miriyala, Ashok"},{"display":"Kalmus, Joachim","given":"Joachim","role":"aut","family":"Kalmus"},{"family":"Falcone","given":"Alfredo","role":"aut","display":"Falcone, Alfredo"},{"given":"Alberto","role":"aut","family":"Zaniboni","display":"Zaniboni, Alberto"}],"note":["Gesehen am 06.03.2020","Published online: September 6, 2018"],"recId":"1691851124","language":["eng"],"relHost":[{"id":{"doi":["10.1002/(ISSN)1549-490X"],"eki":["32063020X"],"issn":["1549-490X"],"zdb":["2023829-0"]},"part":{"text":"24(2019), 2, Seite 185-192","year":"2019","issue":"2","pages":"185-192","volume":"24","extent":"8"},"pubHistory":["1.1996 -"],"origin":[{"publisherPlace":"Oxford ; Miamisburg, Ohio ; Hoboken, NJ","dateIssuedKey":"1996","publisher":"Oxford University Press ; AlphaMed Press ; Wiley","dateIssuedDisp":"1996-"}],"disp":"Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy results of the large, single‐arm, open‐label phase IIIb CONSIGN studyThe oncologist","title":[{"title_sort":"oncologist","title":"The oncologist","subtitle":"the international peer-reviewed journal for the practicing oncologist, hematologist"}],"note":["Gesehen am 19.04.2022"],"recId":"32063020X","language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"physDesc":[{"extent":"Online-Ressource"}]}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"8 S."}],"name":{"displayForm":["Eric Van Cutsem, Erika Martinelli, Stefano Cascinu, Alberto Sobrero, Maria Banzi, Jean‐François Seitz, Carlo Barone, Marc Ychou, Marc Peeters, Baruch Brenner, Ralf Dieter Hofheinz, Evaristo Maiello, Thierry André, Andrea Spallanzani, Rocio Garcia‐Carbonero, Yull E. Arriaga, Udit Verma, Axel Grothey, Christian Kappeler, Ashok Miriyala, Joachim Kalmus, Alfredo Falcone, Alberto Zaniboni"]}} | ||
| SRT | |a VANCUTSEMEREGORAFENI2019 | ||